Opicapone In Clinical Practice In Parkinson'S Disease Patients With Motor Fluctuations And Complications Of Therapy At Baseline: Findings From The Optipark Study

Opicapone (OPC) proved to be effective for end-of-dose motor fluctuations (MF) in Parkinson's disease (PD) patients. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of patients treated in real-world conditions. We evaluated OPC's effects in patients with MF and complications of therapy (CoT) at baseline.